Thermo Fisher Scientific Inc., US8835561023

Thermo Fisher schedules results as Thermo Fisher Scientific stock costs EUR 592.70

Published on 10/01/2026 at 16:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue rose 10.00 percent to USD 11.99 billion. Thermo Fisher Scientific stock costs EUR 592.70 on October 1, 2026 versus EUR 596.60.

Trading-Floor mit großen Bildschirmen, Kursdiagrammen und DNA-Grafiken, Händler an Arbeitsplätzen — Börsen-Editorial visualisiert Thermo Fisher Sci. US8835561023 mit Handelssaal, Kursdiagrammen und Biotech-Molekülgrafiken auf Bildschirmen, Illustration mit AI erstellt.

Thermo Fisher Scientific (ISIN US8835561023) was trading at EUR 592.70 at Lang & Schwarz on October 1, 2026 at 4:02 p.m. CEST, down 0.65 percent versus the prior close of EUR 596.60. According to Thermo Fisher Scientific on September 28, 2026, the company will release third-quarter 2026 results before the market opens on October 21, 2026.

Second-quarter growth broadens

Fortune reported that Thermo Fisher's second-quarter 2026 revenue increased 10.00 percent to USD 11.99 billion. Adjusted operating income rose 15.00 percent to USD 2.73 billion, lifting adjusted operating margin by 0.90 percentage points to 22.80 percent.

The same second-quarter transcript shows adjusted earnings per share increased 13.00 percent to USD 6.03, while GAAP earnings per share rose 9.00 percent to USD 4.68. The contrast matters: adjusted operating income grew faster than revenue, pointing to operating leverage during the latest reported quarter.

Guidance moves higher

Management raised its 2026 outlook in the July 23, 2026 earnings call. Fortune reported a revenue guidance range of USD 47.40 billion to USD 48.10 billion and adjusted earnings per share guidance of USD 24.93 to USD 25.33, representing adjusted earnings per share growth of 9.00 percent to 11.00 percent over 2025.

The updated outlook also calls for organic revenue growth of 3.00 percent to 4.00 percent in 2026, with the company expecting the upper end of that range. First-half organic growth was 3.00 percent, so the second-half expectation represents a 1.00 percentage-point increase in the growth rate.

Analysts set a wide valuation range

According to MarketBeat, UBS upgraded Thermo Fisher from Neutral to Buy on September 9, 2026 and raised its price target from USD 540.00 to USD 730.00. Deutsche Bank reiterated a Buy rating with a USD 720.00 target on September 25, 2026.

MarketBeat's latest panel covered 26 analysts, with 20 Buy ratings, 4 Holds and 2 Sells. Its average target was USD 628.78, while the highest and lowest targets were USD 750.00 and USD 520.00, respectively, highlighting a split between the upgraded individual targets and the wider consensus.

Stock trades below prior close

The Lang & Schwarz quote stood at EUR 592.70 on October 1, 2026 at 4:02 p.m. CEST, compared with a prior close of EUR 596.60 and a daily change of minus 0.65 percent. The primary listing is on the NYSE, where the finance quote showed USD 668.45 at 10:08 a.m. ET on October 1, 2026; the separate currency and venue make it context rather than a replacement for the euro reference price. The market capitalization was USD 247.2 billion, and the 52-week range was USD 435.27 to USD 683.63, both as of October 1, 2026. The further course of trading is shown by the continuously updated real-time quote of Thermo Fisher Scientific stock.